Merck has announced its acquisition of Terns Pharmaceuticals for $6.7 billion, a significant investment aimed at enhancing its capabilities in oncology.
Terns Pharmaceuticals is recognized for its development of a promising treatment for leukemia, which aligns with Merck's strategic focus on expanding its therapeutic offerings.
This acquisition may lead to increased capacity in Merck's oncology pipeline, potentially impacting treatment options and market dynamics in the leukemia sector.